Mode of action and tissue dosimetry considerations in interspecies extrapolation

Human and Ecological Risk Assessment

Volumn 13, Issue 1, 2007, Pages 101-110

  Andersen, Melvin E ^a  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 33847172195     PISSN: 10807039     EISSN: 15497860     Source Type: Journal    
DOI: 10.1080/10807030601105431     Document Type: Review

References (37)

1. Albert RE, Train RE, and Anderson E. 1977. Rationale Developed by the Environmental Protection Agency for the Assessment of Carcinogenic Risks. J Natl Cancer Inst 58(5):1537-41
2. Andersen ME, Clewell HJ III, Gargas ML, et al. 1987. Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205
3. Andersen ME, Clewell HJ III, and Krishnan K. 1995. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. J Risk Anal 15:533-7
4. Andersen ME, Birnbaum LS, Barton HA, et al. 1997. Regional Hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-Tetrachlorodibenzo-p-diocin evaluated with a multi-compartment geometric model of hepatic zonation. Toxicol Appl Pharmacol 144:145-55
5. Andersen ME, Conolly RB, Gaido KW, et al. 2005a. Dose-response modeling in the systems biology era. Reprod Toxicol 19:327-37
6. Andersen ME, Dennison JE, Thomas RS, et al. 2005b. New directions in incidence-dose modeling. Trends in Biotechnol 23:122-37
7. Andersen ME, Reddy MB, and Plotzke KP. 2005c. Cyclic siloxanes do not bioaccumulate with repeated, episodic exposures. The Toxicologist 84:175
8. Anderson ME, Reddy MB, and Plotzke KP. 2007. Repeated, periodic inhalation exposures to octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane do not result in bioaccumulation. Toxicol Sci (in review)
9. Barton HA, Andersen ME, and Clewell HJ III. 1998. Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and non-cancer risk assessment. Hum Ecol Risk Assess 4:75-115
10. Clewell HJ III and Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. Toxicol Ind Health 1:111-31
11. Clewell HJ III and Andersen M. 1996. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315-29
12. Clewell HJ, Gentry R, Gearhart JM, et al. 2001. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK Model. Science Total Environ 274:37-66
13. Conolly RB, Kimbell JS, Janszen D, et al. 2003. Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. Toxicol Sci 75:432-47
14. Conolly RB, Kimbell JS, Janszen D, et al. 2004. Human respiratory tract cancer risks of inhaled formaldehyde: Dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset. Toxicol Sci 82:279-96
15. Dedrick RL. 1973. Animal scale-up. J Pharmacokinet Biopharm 1:435-61
16. Dourson ML. 1993. Reference dose of the Environmental Protection Agency. Scand J Work Environ Health. 19(Suppl 1):115-18
17. Dourson ML and Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Reg Toxicol Pharmacol 3:224-38
18. Gehring PJ, Watanabe PG, and Park CN. 1978. Resolution of dose-response toxicity data for chemicals requiring metabolic activation: Example-vinyl chloride. Toxicol Appl Pharmacol 44:581-91
19. Gerlowski LE and Jain RJ. 1983. Physiologically based pharmacokinetic modeling: Principles and applications. J Pharm Sci 72:1103-26
20. Himmelstein K and Lutz RJ. 1979. A review of the application of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm 7:127-37
21. Kohn MC, Sewall CH, Lucier GW, et al. 1996. Mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol 136:29-48
22. Lehman AJ and Fitzhugh OG. 1954. 100-Fold Margin of Safety. Assoc Food Drug Off U.S.Q. Bull 18:33-5
23. Leung HW. 1991. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J Toxicol Environ Health 32:247-67
24. NRC (National research Council). 1987. Dose-route extrapolation: Using inhalation toxicity data to set drinking water limits. In: Drinking Water and Health, Vol. 6, Chap. 6. National Academy Press, Washington, DC, USA
25. O'Flaherty E. 1989. Interspecies conversion of kinetically equivalent doses. Risk Anal 9:587-98
26. Portier CJ and Kaplan N L. 1989. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: Methylene chloride. Fund Appl Toxicol 13:533-44
27. Price PS, Conolly RB, Chaisson CF, et al. 2003. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 33:469-503
28. Reddy MB, Andersen ME, Morrow PE, et al. 2003. Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Toxicol Sci 72:3-18
29. Renwick AG. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contam 10:275-305
30. Sarangapani R, Teeguarden J, Reitz RH, et al. 2003. Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: Analysis using a physiologically based pharmacokinetic model. Toxicol Sci 71:41-52
31. Travis CC and White RK. 1989. Interspecies scaling of toxicity data. Risk Anal 8:116-25
32. USEPA (US Environmental Protection Agency) 1986 Guidelines for carcinogen risk assessment. Fed Regist 51:33992
33. USEPA. 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. USEPA/600/90/066F. Office of Research and Development, Washington, DC, USA
34. USEPA. 2003. A Framework for a Computational Toxicology Research Program in ORD. EPA/600/R-03/065. Office of Research and Development, Washington, DC, USA
35. USEPA. 2004: An Examination of EPA Risk Assessment Principles and Practices. EPA/100/B04-001. Washington, DC, USA
36. Wagner JG. 1981. History of pharmacokinetics. Pharmacol Ther 12:537-62
37. Wang X, Santostefano MJ, Evans MV, et al. 1997. Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats. Toxicol Appl Pharmacol 147:151-68